1. oktoober 2007

Tähelepanu! Artikkel on enam kui 5 aastat vana ning kuulub väljaande digitaalsesse arhiivi. Väljaanne ei uuenda ega kaasajasta arhiveeritud sisu, mistõttu võib olla vajalik kaasaegsete allikatega tutvumine.

Robert J. Coury- Mylan's Vice Chairman and Chief ExecutiveOfficer said- "The new Mylan now has all of the critical attributeswe need to ensure future success and deliver powerful growth. Wehave enhanced scale and stability- a truly global reach- verticaland horizontal integration- and breadth and depth in our managementteam. Most importantly- we have a common purpose and dedication toexecuting on our strategy and delivering superior shareholderreturns."

The new Mylan is the third largest generic company worldwide-employs more than 11-000 people and has a global presence in morethan 90 countries. Mylan's broad product offering now includes morethan 570 products and the world's second largest portfolio ofactive pharmaceutical ingredients (APIs) with 126 U.S. drug masterfiles (DMFs). Mylan has a powerful global pipeline with more than255 applications or dossiers pending regulatory approval. The newMylan will benefit from substantial operational efficiencies andeconomies of scale from increased sales volumes and its verticallyand horizontally integrated platform. Dey- Mylan's specialtypharmaceuticals business- brings additional exciting anddiversified opportunities through its existing strengths in therespiratory arena.